MIRA Pharmaceuticals Reports SKNY-1 Weight and Fat Reduction in Obese Mice
MIRA Pharmaceuticals reported that oral SKNY-1 significantly reduced weight and fat in obese mice, with favorable lean-mass and weight-regain findings versus semaglutide.
Related stories
PAG to Acquire 51% Stake in Evergrande Property Services for $514 Million
PAG will acquire a 51% stake for HK$4.03 billion ($513.64 million), Evergrande Property Services said. The offer values 5.52 billion shares at HK$0.8359 each, a 29% discount to the
M impact | EQUITY | Oct 30, 2026, 12:19 AM UTC
Japan's Nikkei Share Average Falls 1.1%
M impact | EQUITY | Oct 30, 2026, 12:06 AM UTC
Hammond Power Solutions Reports Quarterly Results
The company reported results for the quarter ended September 30; no financial figures were provided.
M impact | EQUITY | Oct 30, 2026, 12:06 AM UTC
Tokyo Electron Shares Fall 4%
M impact | EQUITY | Oct 30, 2026, 12:05 AM UTC
South Korea’s Kospi falls 3%
M impact | EQUITY | Oct 30, 2026, 12:03 AM UTC
Coles Shares Slip as Competition Dents Early Second-Quarter Sales
Coles shares slipped as intense competition weighed on early second-quarter sales.
L impact | EQUITY | Oct 30, 2026, 12:03 AM UTC